1. The cell line models to study tyrosine kinase inhibitors in non-small cell lung cancer with mutations in the epidermal growth factor receptor: A scoping review.
- Author
-
Belloni, Alessia, Pugnaloni, Armanda, Rippo, Maria Rita, Di Valerio, Silvia, Giordani, Chiara, Procopio, Antonio Domenico, and Bronte, Giuseppe
- Subjects
- *
ERLOTINIB , *NON-small-cell lung carcinoma , *EPIDERMAL growth factor receptors , *PROTEIN-tyrosine kinase inhibitors , *CELL lines , *LUNG cancer - Abstract
Non-Small Cell Lung Cancer (NSCLC) represents ∼85% of all lung cancers and ∼15–20% of them are characterized by mutations affecting the Epidermal Growth Factor Receptor (EGFR). For several years now, a class of tyrosine kinase inhibitors was developed, targeting sensitive mutations affecting the EGFR (EGFR-TKIs). To date, the main burden of the TKIs employment is due to the onset of resistance mutations. This scoping review aims to resume the current situation about the cell line models employed for the in vitro evaluation of resistance mechanisms induced by EGFR-TKIs in oncogene-addicted NSCLC. Adenocarcinoma results the most studied NSCLC histotype with the H1650, H1975, HCC827 and PC9 mutated cell lines, while Gefitinib and Osimertinib the most investigated inhibitors. Overall, data collected frame the current advancement of this topic, showing a plethora of approaches pursued to overcome the TKIs resistance, from RNA-mediated strategies to the innovative combination therapies. [Display omitted] • 228 original articles have been collected from 1999 to March 2023. • H1650, H1975, HCC827 and PC9 are the most employed NSCLC mutated cell lines. • Afatinib, Erlotinib, Gefitinib and Osimertinib are the most investigated EGFR-TKIs. • Knockdown and combined approaches were pursued to overcome the TKIs resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF